Companies news of 2009-10-31 (page 1)

  • Sierra Vista Bank Reports 3rd Quarter 2009 Financial Results
  • L'offre de Noront sur Freewest continue de représenter une juste valeur totale
  • Magna International Inc. - Annonce d'une conférence téléphonique pour communiquer...
  • Kingsway Financial announces upcoming event
  • Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI)...
  • Aftersoft Network N.A. Inc Announces Release of OpenWebs Version 5
  • Perfect World Announces Appointment to the Board of Directors
  • Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis...
  • BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 DiabetesPrescribing...
  • Entergy Issues Forward Looking Financial Update and Announces $750 Million Share...
  • Fannie Mae publie son résumé mensuel de septembre 2009

    Sierra Vista Bank Reports 3rd Quarter 2009 Financial Results

    FOLSOM, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Sierra Vista Bank (OTC Bulletin Board: SVBA), recently announced its financial results for the Quarter ending September 30, 2009. Assets increased during the 3rd Quarter by $4.7 million to $91.9 million; deposits increased by $3.2 million to $75.7 million; and loans increased by $10.1 million to $72.0 million. Gregory Patton, President and CEO noted:

    "There continue to be good clients looking for a lending or deposit home with bankers who understand and care about their financial success. We've been successful at finding a number of those during this quarter."

    Year over year growth for assets was $36.3 million or 65.3%; deposits increased $34.6 million or 84.2%; and loans increased $28.4 million or 65.2%.

    Total revenues for the 3rd Quarter 2009 were $1,371,000, an 87.6% increase when compared to $731,000 in the 3rd Quarter 2008. Net interest income increased in the 3rd Quarter to $890,000, double from the $443,000 in the 3rd Quarter 2008. The Bank continues to be able to lower its cost of funds enough to increase the net interest margin to over 4.0% at the end of the 3rd Quarter. This was accomplished even in a flat loan rate environment. The total loan loss provision for the 3 months was $1,134,000, bringing the reserve to 2.31% of total loans. The Bank's non-accrual loans at September 30, 2009 totaled $2,807,000; an increase of $137,000 over the June 30, 2009 non-accrual loan total. Management is actively working with each credit and has reserved or charged off any amounts we believe to be in excess of a reasonable recovery estimate. Total loans charged off in the 3rd Quarter of 2009 were $528,000 which included four loans, one of which became uncollectible and three were written down to market or collateralized value. "The economic conditions and the length of this recession have and will continue to impact good people who were operating good businesses. We are going to be aggressive in our identification and reservation of funds to protect the future of the Bank," stated Patton.

    Total revenues for the first 9 months of 2009 were $3,744,000 compared to $1,917,000 for the 9 months ending September 30, 2008 or a 95.3% increase. Net interest income for the first 9 months of 2009 was $2,217,000 compared to $1,173,000 at September 30, 2008 or an 89.0% increase. Year to date loss for the first 9 months of 2009 was ($2,018,156) compared to a net loss at September 30, 2008 of ($1,236,251). The increase in costs for the 2009 period over 2008 are related to both additional provision for loan losses, an increase to the general loan loss reserve, and operating the new branch in Cameron Park which opened in November 2008. "It is a challenging time to be in a start up mode but we are progressing nicely toward a strong financial future," noted Patton.

    Non-interest expense decreased in the 3rd Quarter of 2009 to $1,086,000 from $1,090,000 in the 2nd Quarter 2009. Lesa Fynes, Executive Vice President and Chief Financial Officer commented, "The Bank continues to grow into its fixed operating and overhead costs." The net loss for the 3rd Quarter of 2009 totaled ($1,177,391) compared to a loss in the 2nd Quarter of ($336,676). The 3rd Quarter loss of ($1,177,391) includes the loan loss provision for the quarter of $1,134,000.

    Management continues to closely monitor every area of the Bank to ensure overall profitability and loan quality as it continues into the final quarter of the year.

    About Sierra Vista Bank

    Sierra Vista Bank is a locally owned community bank headquartered at 1710 Prairie City Road in Folsom, California since March 2007, and a branch located in the Sam's Town Center in Cameron Park. The Bank prides itself on serving the financial needs of small businesses and professionals in Folsom and throughout the Highway 50 Corridor and is committed to community philanthropy. Additional information about Sierra Vista Bank can be found at or by calling (916) 850-1500.

    Forward Looking Statement:

    This release may contain forward-looking statements that are subject to risks and uncertainties. Such risks and uncertainties may include but are not necessarily limited to fluctuations in interest rates, inflation, government regulations and general economic conditions, and competition within the business areas in which the Bank will be conducting its operations, including the real estate market in California and other factors beyond the Bank's control. Such risks and uncertainties could cause results for subsequent interim periods or for the entire year to differ materially from those indicated. You should not place undue reliance on the forward-looking statements, which reflect management's view only as of the date hereof. The Bank undertakes no obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.

    Sierra Vista Bank

    CONTACT: Gregory Patton, President/CEO, Sierra Vista Bank,
    +1-916-850-1515,; or Lesa Fynes, EVP/CFO, Sierra
    Vista Bank, +1-916-850-1505,

    Web Site:

    L'offre de Noront sur Freewest continue de représenter une juste valeur totale

    TORONTO, October 31 /PRNewswire/ -- Symbole : NOT:TSX-V

    Actions en circulation : 163 631 957

    Entièrement diluées : 173 461 957

    Noront Resources Ltd. (<< Noront >> ou la << Société >>) (TSX Venture : NOT) a le plaisir de communiquer les commentaires suivants en réponse à la circulaire des directeurs déposée le 27 octobre 2009 par Freewest Resources Canada Inc. (<< Freewest >>).

    - Les actionnaires de Freewest bénéficieront d'une juste valeur totale et d'une prime d'émission significative ;

    - Tous les actionnaires seront impliqués dans les découvertes de nickel-cuivre de haute qualité ;

    - Tous les actionnaires tireront avantage d'un chromite plus solide en plus grande quantité ;

    - La valeur actionnariale sera renforcée par une infrastructure commune et l'efficacité des opérations ;

    - Tous les actionnaires tireront bénéfice de l'expertise mondiale démontrée par la direction de Noront dans le développement de projets;

    - Tous les actionnaires tireront avantage d'une trésorerie autonome et non sujette à dilution à cours terme ;

    - Tous les actionnaires tireront bénéfice d'une liquidité des actions améliorée ;

    - Les différences entre les informations du Droit des actionnaires de Freewest, présentes sur la circulaire de sollicitation de procurations de la direction de Freewest, et celles du plan lui-même, questionnent la validité de l'approbation obtenue des actionnaires.

    Noront faire part de sa déception sur la recommandation des directeurs de Freewest de rejeter son offre d'acquérir toutes les actions ordinaires de Freewest. Noront réitère que l'offre d'échange d'actions soumise à Freewest le 13 octobre 2009, soit 0,25 (1/4) d'une action ordinaire Noront et $0,0001 CAD pour chaque action ordinaire Freewest (<< l'Offre >>), représente une juste valeur. L'Offre restera valide jusqu'au 18 novembre 2009, 17 heures (heure locale à Toronto).

    Wes Hanson, président-directeur général de Noront a déclaré : << Le comité de direction de Freewest omet de reconnaitre la logique commerciale irréfutable et le potentiel de création de valeur actionnariale associé que représenterait la rationalisation du Ring of Fire, par le partage de la lourde charge des coûts d'investissement en infrastructures entre les projets. La circulaire des directeurs de Freewest ne fournit aucune argumentation convaincante soutenant sa recommandation aux actionnaires de rejeter l'Offre. Tenant compte de la dynamique de l'offre et la demande sur le marché de la chromite et, bien que prometteur, du stade précoce de l'exploration actuelle, Noront considère que la valeur proposée aux actionnaires de Freewest est juste. >> Il a ajouté : << Les actionnaires de Freewest ont les moyens de décider si les opportunités que l'Offre représente leur bénéficieront sur le long terme. Nous pensons qu'ils comprendront la logique de l'Offre et par conséquent soumettront leurs actions. >>

    L'Offre représente une juste valeur totale

    L'Offre fournirait aux actionnaires de Freewest une valeur supérieure comparée à la décision de garder Freewest indépendant :

    - L'Offre étant une opération d'échange d'actions au comptant, les actionnaires de Freewest continueront, si l'Offre est menée à bien, à tirer bénéfice de développements significatifs du Ring of Fire, en possédant des actions Noront. Par ailleurs, ils continueront à partager toute augmentation future de la valeur liée au développement et aux opérations du portefeuille existant détenu à 100% par Noront, comprenant :

    - Eagle's Nest, où les derniers résultats de géophysique et de forage annoncés le 15 octobre 2009, ont joint les lentilles A, B et C, démontrant une minéralisation de nickel et cuivre et de sulfure MGP sur plus de 900 mètres;

    - Les gisements de Blackbird où une estimation première de ressources NI 43-101 sera finalisée au quatrième trimestre 2009 ;

    - La découverte de la zone d'or des Trois J annoncée le 27 octobre 2009 ; et les gisements de Freewest, qui incluent :

    - Le gisement de chromite de Black Thor détenu à 100% ;

    - Un intérêt de 50 % dans le gisement de chromite Big Daddy ;

    - Pour qu'un gisement soit dit de "classe internationale", il ne doit pas seulement être de taille importante mais également avoir de faibles coûts d'exploitation, justifier les besoins en capitaux et générer un retour sur investissement supérieur au secteur, diminuant ainsi le risque. La rationalisation des activités sur le Ring of Fire ouvriront la voie du partage des infrastructures et des coûts logistiques essentiels, donnant lieu à :

    - des retours sur investissements accrus et des économies d'échelle;

    - des coûts d'exploitation plus faibles pour l'ensemble des gisements du Ring of Fire de Noront et de Freewest ;

    - des coûts d'investissement répartis de façon égale et

    - une valeur actionnariale significativement renforcée ;

    - Noront a offert aux actionnaires Freewest une prime d'émission implicite calculée sur une période calendaire de 30 jours, sur la base moyenne pondérée du volume << MPVP 30 jours calendaires >> avant l'annonce de l'Offre, représentative des primes versées sur des opérations comparables (comme indiqué ci-dessous). Pour consulter les démonstrations, cliquez sur ce lien :

    Noront pense qu'une MPVP de 30 jours calendaires est une mesure raisonnable car elle supprime l'impact des irrégularités commerciales juste avant que toute offre ne soit faite ;

    - Le prix de l'action de Freewest avant l'Offre a dépassé le prix proposé de l'action pendant seulement 10 jours de cotation depuis août 2007, au moment de la première annonce de Noront sur la découverte du Ring of Fire, et pas une seule fois au cours des 18 mois. Noront pense que la performance du prix de l'action ces dernières semaines a été engendrée par l'Offre et n'est due à aucun autre facteur ;

    - Les actions ordinaires de Noront sont significativement plus liquides que les actions ordinaires de Freewest (sur les 12 derniers mois, avant l'annonce de Noront de son intention de faire l'Offre, le volume moyen de transactions quotidien était près de 10 fois celui de Freewest), permettant aux actionnaires de se défaire plus facilement de leurs avoirs sans affecter le prix de l'action sous-jacent.


    - La société combinée détiendra plus de 1 223 kilomètres de terrain de concessions potentielles et viables sur le Ring of Fire, comparés aux quelques 23 kilomètres carrés actuels de terrain pour Freewest.

    - En dépit du statut actuel de Clarence Stream en tant que << actif clé minier >> pour Freewest, Noront remarque que :

    - Freewest n'a identifié qu'une ressource de 400 000 onces d'or au cours des 10 dernières années sur la mine;

    - elle a vendu en option 50% du projet à une société privée en 2007 ;

    - depuis lamise en option de la mine, elle n'a publié aucun résultat de rendement.

    En dépit de la suggestion de Freewest et des rumeurs constantes d'autres alternatives sur le marché, l'Offre est l'unique proposition de bonne foi proposée actuellement aux actionnaires de Freewest. Toute option concurrente à cette Offre n'est qu'hypothétique et ne constitue aucune alternative réelle.

    Par ailleurs, nous notons avec intérêt que l'épouse de Ronald Kay, président-directeur de Freewest, a vendu 50 000 parts de Freewest deux jours après l'annonce de l'intention de Noront de faire cette Offre.

    Stratégie de développement de Noront sur le Ring of Fire

    La direction de Noront a été mandatée par son comité directeur pour explorer et développer agressivement le Ring of Fire de la manière la plus optimale et la moins dilutive. L'équipe de direction actuelle comprend 5 cadres qui possèdent une vaste expérience dans le domaine de l'exploration, de la modélisation de projet et des ressources, de la métallurgie, de la conception, des finances et de la construction et développement de projets. Ilstotalisent plus de 120 années d'expérience, incluant la participation au développement et à l'expansion de plus de 25 projets miniers mondiaux dont les investissements totalisent plus de 10 milliards de dollars USD. Plusieurs de ces projets ont eu à faire face à des défis similaires à ceux du Ring of Fire, notamment Diavik, Baie de Voisey, Maricunga et Fort Knox. La combinaison de Freewest et Noront offrirait à tous les actionnaires le bénéfice de cette expertise confirmée dans le développement de projets. Par ailleurs, avec des fonds de roulement combinés anticipés à quelques 37 millions de dollars canadiens, le groupe disposerait d'un financement suffisant pour faire avancer tous ses projets sur le Ring of Fire, sans aucune dilution à court terme.

    Le comité et la direction de Noront participent collectivement à réunir environ 12 milliards de dollars US en capitaux propres et capitaux empruntés pour des projets miniers dans le monde.

    Noront fut la première société à reconnaitre le potentiel de chromite sur le Ring of Fire, fait démontré par la réalisation de la première estimation de ressource de NI 43-101 au Canada pour son gisement de chromite de Blackbird. A ce jour, Noront à engagé plus de 20 millions de dollars CAD en exploration et évaluation de son gisement de chromite de Blackbird.

    Noront maintient que le développement des opérations minières de chromite sur le Ring of Fire sera difficile et comportera une lourde charge de coûts d'investissement en infrastructure, nécessaire pour accéder aux marchés mondiaux. Noront considère que le partage des infrastructures et de la logistique entre le gisement de nickel à haute teneur, cuivre et PGM d'Eagle Nest et les découvertes de chromite des deux sociétés, renforceront de façon significative toute l'économie du projet et générera une valeur actionnariale importante en créant des gisements de niveau international, accessibles. Les synergies d'infrastructures entre les découvertes du Ring of Fire sont meilleures si une des parties détient tous les projets. Noront considère la rationalisation des activités du Ring of Fire comme la conduite la plus logique et qui profite au mieux aux actionnaires.

    Découvertes de chromite sur le Ring of Fire

    Sur la base sur le nombre limité de forages réalisés par d'autres sociétés actives sur le Ring of Fire, Noront pense que la teneur, l'épaisseur, les rapports chromite-fer et les résultats métallurgiques laissent supposer une forte probabilité de plusieurs gisements de chromite presque semblables dans la région en termes de qualité, de vie minière et de viabilité économique. Par exemple, les découvertes de la campagne de forages de Freewest à ce jour ne différent pas de ceux de Blackbird, où plusieurs intervalles solides ont été entrecoupés, comprenant 39,6% Cr(2)O(3) sur 69,6 mètres, 42,3% Cr(2)O3 sur 40,5 mètres et 38,2% Cr(2)O3 sur 74.9 mètres (les résultats de ces forages ont été communiqués le 20 juillet 2008 et le 23 septembre 2008). L'analyse de Noront des informations publiques disponibles suggère que Black Thor serait plus vaste que les gisements de Blackbird, mais de qualité inférieure. Les unités massives du gisement de Blackbird comprennent des teneurs en Cr(2)O3 de plus de 40% et un rapport chromite-fer dépassant généralement 2:1, mesures largement supérieures au rapport sur Black Thor rendu public par Freewest. Le rapport chromite-fer de 2:1 de Blackbird est très enviable car il affecte positivement la production de ferrochrome en réduisant les coûts d'énergie du processus de fusion.

    Noront fait les observations suivantes à l'égard du commentaire de Freewest stipulé dans la circulaire des directeurs concernant les caractéristiques de leur Black Thor et nos découvertes de chromite de Blackbird :

    - Contrairement au complexe Bushveld d'Afrique du Sud où la géologie est bien connue et les lits de chromite forés depuis plus d'un siècle, Noront pense qu'avec seulement 54 puits de forage réalisés sur Black Thor, l'espacement actuel du forage n'est pas suffisant pour permettre des conclusions scientifiques sur la variabilité de la qualité de ce gisement de chromite, dans le cadre d'une région de chromite nouvelle ;

    - Les conclusions auxquelles Freewest a abouti concernant la minéralisation de Blackbird comme étant << précoce >> et discontinue sont non fondées : le modèle géologique de Noront mentionné par Freewest était un modèle provisoire incomplet développé par ses géologues de Noront sur site pour contrôler les résultats du forage. Le modèle actuel de ressources de Noront pour le gisement de Blackbird est en cours de réalisation par Micon International et n'a pu être consulté par Freewest à l'époque ; Freewest n'a pas été capable de générer de la valeur pour ses actionnaires à partir du Ring of Fire.

    En ajustant le prix de l'action ordinaire de Freewest à la valeur de l'avoir Freewest de Quest Uranium, la valeur implicite des autres actifs de Freewest (en particulier des actifs du Ring of Fire), sur la base d'une action, a diminué entre le 11 janvier 2008, date à laquelle Quest Uranium est entré en cotation et le 2 octobre 2009, dernier jour de cotation immédiatement avant l'annonce de Noront de son intention de faire l'Offre (voir l'illustration ci-dessus). Pour consulter la démonstration, cliquez sur le lien :

    Démonstration que Freewest n'a pas été capable de générer de valeur pour ses actionnaires à partir du Ring of Fire.

    Plan des Droits des actionnaires de Freewest

    Noront ne considère pas que le Plan des Droits des actionnaires (le << Plan >>) et les tactiques de retard associées doivent être utilisés pour préserver les postes de direction aux dépens des actionnaires de Freewest. Nous demandons à tous les actionnaires de Freewest de considérer l'Offre dans les délais autorisés par la législation applicable sur les titres.

    En ce qui concerne le Plan, Noront a indiqué dans sa circulaire d'offre publique d'achat qu'il existait des différences entre les informations sur le Plan dans la circulaire de sollicitation de procurations de la direction de Freewest, pour la réunion au cours de laquelle les actionnaires de Freewest ont approuvé le Plan décrit, comparé au Plan qui avait été finalement déposé au SEDAR. Ces différences, liées principalement à la définition d'une << Offre autorisée >>, questionnent la validité de l'approbation du Plan par les actionnaires et en conséquence, la valeur légale du Plan ou l'utilisation de ce Plan pour priver les actionnaires de leur droit de décider d'accepter cette Offre. Noront a soulevé ces inquiétudes auprès de l'organisme réglementaire sur les titres du Québec et entend poursuivre son action avec cet organisme sur ce sujet ainsi que sur d'autres questions liées au Plan, ce afin que les actionnaires soient libres de prendre leur propre décision conformément aux politiques des organismes réglementaires sur les titres.

    Noront note également que la circulaire des directeurs de Freewest reprend certaines informations erronées ou trompeuses contenues dans la circulaire de sollicitation de procurations de la direction concernant le Plan. Premièrement, la circulaire des directeurs déclare qu'une offre concurrente autorisée doit satisfaire à toutes les exigences d'une << Offre autorisée >>, alors qu'en réalité une offre concurrente peut avoir une période de validité inférieure aux 60 jours requis pour une offre autorisée. Par ailleurs, la circulaire déclare que le comité directeur peut racheter les droits en circulation, à tout moment avant l'occurrence de << l'évènement de prise de contrôle >>, alors qu'en réalité le comité directeur ne peut racheter les droits sans autorisation préalable des actionnaires ou des détenteurs des droits.

    Pour que l'Offre puisse être concrétisée, le Plan doit être résilié ou des poursuites doivent être engagées par le comité directeur de Freewest, une commission des titres ou tribunal de juridiction compétent pour supprimer l'effet du plan et permettre à l'Offre d'avoir lieu. Si la transaction du Plan n'est pas résiliée, Noront peut être forcé de retirer l'Offre.

    Noront encourage vivement les actionnaires de Freewest à lire la circulaire d'Offre publique d'échange qui contient l'intégralité des termes et conditions de l'Offre ainsi que les instructions précises de la manière dont les actionnaires peuvent soumettre leurs actions ordinaires à l'Offre. Des exemplaires de la circulaire de l'offre publique d'échange et les documents associés sont disponibles sur ou sur SEDAR

    Les actionnaires de Freewest qui choisissent de soumettre leurs actions à l'Offre doivent remplir la lettre de transmission ou, le cas échéant, l'avis d'exécution garantie (ces deux documents accompagnent la circulaire de l'offre publique d'achat) et renvoyer les documents concernés conformément aux termes et conditions définis de manière plus exhaustive en section 3 << Moyen d'Acceptation >> de l'Offre. Si les actions ordinaires de Freewest sont détenues au nom d'un mandataire tel que courtier, banque d'investissement, banque ou société de fiducie, l'actionnaire contactera ce mandataire pour lui donner les instructions afin de soumettre ses actions ordinaires à l'Offre.

    Pour toute assistance à la soumission d'actions à l'Offre de Noront, les actionnaires de Freewest sont encouragés à contacter

    Laurel Hill Advisory Group au numéro de téléphone suivant : +1-877-304-0211.

    À propos de Noront :

    Noront Resources Ltd. concentre ses activités sur ses nombreuses découvertes significatives de nickel-cuivre-platine-palladium à haute teneur, de chromite, d'or et de vanadium, dans une région connue sous le nom de << Ring of Fire >>, région multi-métallifère émergente située dans les basses terres de la Baie de James en Ontario, au Canada. Noront est le principal propriétaire du Ring of Fire, et continue de se démarquer et de révéler ses découvertes par des rapports techniques et économiques NI 43-101, et par un ambitieux plan de forage bien financé sur le reste de l'année 2009 et l'année 2010.

    Toutes les informations sur la société peuvent être consultées sur son site Internet, à l'adresse ou sur le site de SEDAR sur

    Wesley (Wes) Hanson

    Président-directeur général

    NORONT Resources Ltd.


    Ce communiqué contient des << énoncés prospectifs >> au sens de la législation canadienne en valeurs mobilières applicable, y compris des prédictions, projections et prévisions. Les énoncés prospectifs comprennent, mais ne sont pas limités à, des déclarations qui portent sur les activités, événements ou développements dont la Société prévoit ou anticipe qu'ils aient ou puissent avoir lieu à l'avenir, y compris des éléments tels que la stratégie future d'entreprise, les atouts compétitifs, les objectifs, l'expansion, la croissance des entreprises de la Société, des opérations, des plans et à l'égard des résultats d'exploration, le calendrier et le succès des activités d'exploration en général, le planning des autorisations, la réglementation de l'exploration et de l'exploitation minière, les risques environnementaux, les litiges concernant les titres ou réclamations, les limitations de couverture d'assurance, le calendrier et, éventuellement, les résultats de tout litige et le calendrier et les résultats des estimations de ressources futures ou d'études économiques à l'avenir.

    Souvent, mais non systématiquement, les énoncés prospectifs peuvent être identifiés par l'utilisation de mots tels que << plans >>, << planification >>, << planifié >>, << prévoir >> ou << s'attendre à >>, << ne pas s'attendre à >>, << continue >> << prévu >>, << estimations >>, << prévisions >>, << entend >>, << potentiel>>, << anticipe >>, << n'anticipe pas >>, ou par des croyances ou des descriptions de << but >>, ou par une variation desdits mots et expressions ou l'énoncé selon lequel certaines actions, événements ou résultats << peuvent >>, << devraient >>, << seraient >>, << pourraient >> ou << seront >>, suivi des verbes être entrepris, survenir ou être réalisés.

    Les énoncés prospectifs sont basés sur un certain nombre de facteurs matériels et d'hypothèses, y compris le résultat des activités de forage et d'exploration, le fait que les parties au contrat fournissent des biens et/ou des services dans les délais impartis, le fait que le matériel nécessaire à l'exploration soit disponible dans les temps et ne subisse aucune interruption non prévue, le fait qu'aucune pénurie de main d'oeuvre ni aucun retard ne sont constaté, le fait que le fonctionnement de l'usine et du matériel soit conforme aux spécifications, le fait qu'aucun problème géologique ou technique ne survienne, et le fait que le laboratoire et les autres services connexes sont disponibles et fonctionnent selon ce qui est prévu dans le contrat. Les énoncés prospectifs comportent des risques connus et inconnus, des événement ultérieurs, des conditions, des incertitudes et d'autres facteurs susceptibles d'entraîner une différence matérielle dans les résultats effectifs, les performances ou les réalisations par rapport aux résultats futurs, prédictions, projections, prévisions, performance ou réalisations exprès ou implicites contenues dans ces mêmes déclarations anticipatives. Ces facteurs comprennent, sans toutefois s'y limiter, l'interprétation et les résultats effectifs des activités d'exploration en cours ; des changements dans les paramètres du projet au fur et à mesure que les plans sont affinés ; les cours futurs de l'or ; les écarts possibles dans la teneur ou dans les taux de récupération ; la défaillance du matériel ou des procédés nécessaires aux opérations anticipées ; la défaillance des parties contractantes à réaliser leurs obligations ; des litiges de main d'oeuvre et d'autres risques inhérents à l'industrie minière ; des retards dans l'obtention des accords gouvernementaux ou de financement, ou dans la réalisation de l'exploration, ainsi que les facteurs exposés dans les documents publics de la société. Bien que Noront ait tenté d'identifier les facteurs importants pouvant entraîner des divergences dans les actions, les évènements ou les résultats par rapport à ceux décrits dans les énoncés prospectifs, d'autres facteurs sont susceptibles d'entraîner des différences dans les actions, les évènements ou les résultats par rapport à ce qui était anticipé, estimé ou prévu. Rien ne permet de garantir que les énoncés prospectifs soient précis, car les résultats effectifs et des évènements futurs peuvent différer matériellement de ceux anticipés dans ces déclarations. Il est donc recommandé aux lecteurs de ne se baser sur ces énoncés prospectifs qu'avec prudence.

    Ni TSX Venture Exchange ni son Prestataire en matière de réglementation (selon la définition du terme anglais "Regulation Services Provider" dans les directives de TSX Venture Exchange) n'assument de responsabilité quant au caractère adéquat et précis de ce communiqué de presse.

    Pour de plus amples informations concernant l'Offre, veuillez contacter Wes Hanson, président et président-directeur général ou Joanne Jobin, vice-présidente, Communication Institutionnelle, tél: +1-416-367-1444, ou visitez le site Internet de Noront, à l'adresse suivante :

    Noront Resources Ltd.

    Pour de plus amples informations concernant l'Offre, veuillez contacter Wes Hanson, président et président-directeur général ou Joanne Jobin, vice-présidente, Communication Institutionnelle, tél. : +1-(416)-367-1444, ou visitez le site Internet de Noront, à l'adresse suivante :

    Magna International Inc. - Annonce d'une conférence téléphonique pour communiquer résultats du troisième trimestre 2009

    TORONTO, October 31 /PRNewswire/ -- Magna International Inc. (TSX : MG.A ; NYSE : MGA) communiquera ses résultats financiers pour le troisième trimestre clos au 30 septembre 2009, le jeudi 5 novembre 2009.

    Magna tiendra sa conférence téléphonique trimestrielle le jeudi 5 novembre 2009 à 17h30 EST. Le numéro à appeler pour cette conférence est le +1-800-891-8794. Pour l'étranger, le numéro est le +1-212-231-2912. Veuillez appeler dans les 10 minutes au moins, précédant la conférence. Cette conférence téléphonique sera retransmise sur Internet, sur et sera présidée par Vincent J. Galifi, Vice-président exécutif et Directeur Financier.

    En cas d'indisponibilité à la date prévue, les numéros pour la retransmission sont : Amérique du Nord - +1-416-626-4100 et étranger - +1-800 558-5253 (numéro de réservation : 21442088). Ces retransmissions seront disponibles jusqu'au jeudi 12 novembre 2009.

    Pour de plus amples renseignements : Pour toute question veuillez contacter Louis Tonelli au +1-905-726-7035 ; pour les questions sur la téléconférence, veuillez contacter Karin Kaminski au +1-905-726-7103

    Magna International Inc.

    Pour de plus amples renseignements : Pour toute question, veuillez contacter Louis Tonelli au +1-905-726-7035 ; pour les questions sur la téléconférence, veuillez contacter Karin Kaminski au +1-905-726-7103

    Kingsway Financial announces upcoming event

    TORONTO, Oct. 31 /PRNewswire-FirstCall/ -- Kingsway Financial Services Inc. (TSX:KFS, NYSE:KFS) announced today that it will be releasing its third quarter financial results on the morning of November 6, 2009 with a conference call to follow at 8:30 a.m. To access the call, please dial 1-800-594-3790 about five minutes before the start of the call. An audio web cast will also be broadcast live and can be accessed through our website at or directly at

    About the Company

    Kingsway Financial Services Inc. ("Kingsway" or "the Company") focuses on non-standard automobile insurance in North America. Kingsway's primary businesses are the insuring of automobile risks for drivers who do not meet the criteria for coverage by standard automobile insurers; specialized markets of recreational vehicles such as motorcycles, ATVs and snowmobiles; and commercial automobile insurance. The Company operates through wholly-owned insurance subsidiaries in Canada and the U.S., which it is currently consolidating to reduce overhead and strengthen its competitive position. The common shares of Kingsway Financial Services Inc. are listed on the Toronto Stock Exchange and the New York Stock Exchange, under the trading symbol "KFS".

    Forward-Looking Statements

    This press release includes forward-looking statements that are subject to risks and uncertainties. These statements relate to future events or future performance and reflect management's current expectations and assumptions. The words "anticipate", "expect", "believe", "may", "should", "estimate", "project", "intend", "forecast" or similar words are used to identify such forward-looking information. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of Kingsway. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see Kingsway's securities filings, including its 2008 Annual Report under the heading Risk Factors in the Management's Discussion and Analysis section. The securities filings can be accessed on the Canadian Securities Administrators' website at, and on the EDGAR section of the U.S. Securities and Exchange Commission's website at or Kingsway's website at Kingsway disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Kingsway Financial Services Inc.

    Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual MeetingData Shows Faster Resolution of Diarrhea and Improved Outcome in Patients Requiring Concomitant Antibiotics

    SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.


    Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented results showing that fidaxomicin is associated with faster resolution of diarrhea. In patients with more pronounced diarrhea (ie. not resolving in the first 24 hours of therapy), fidaxomicin was associated with a faster time to resolution of diarrhea than vancomycin (79 hours vs. 105 hours, p=0.056). It is possible that decreasing the duration of diarrhea may have a direct impact on reducing the spread of CDI in healthcare facilities and lowering overall environmental spore contamination, thereby decreasing CDI rates and leading to earlier discharge of CDI patients from the hospital.

    In another presentation, Kathleen M. Mullane, D.O., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented data that indicated fidaxomicin may be a more effective therapy for CDI in patients requiring concomitant antibiotics. Treatment of CDI is often complicated by systemic infections requiring concomitant antibiotics. The analysis indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin, had a significantly improved global cure rate (72% vs. 50%, p=0.022), lower CDI recurrence rate (40% vs. 23%, p=0.061), and higher clinical cure rate (87% vs. 77%, p=0.171).

    "The faster time to resolution of diarrhea and improved outcomes for patients requiring concomitant antibiotics are important factors for physicians to consider when selecting a treatment for CDI," said Michael N. Chang, Ph.D., President and CEO of Optimer Pharmaceuticals. "These additional factors along with the significantly lower recurrence rate and higher global cure rate suggest that fidaxomicin has the potential to be a best in class therapy for CDI."

    For a complete list of posters, please visit the Resources webpage on our web site at

    Fidaxomicin Clinical Study Design

    629 adult subjects were enrolled in this multi-center, randomized, double-blind phase 3 clinical trial, which was the largest such trial for the treatment of CDI. Subjects with confirmed CDI received either 200 mg fidaxomicin dosed orally twice daily or 125 mg Vancocin dosed orally four times daily. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of fidaxomicin was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

    The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence.

    About Clostridium Difficile Infection

    CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

    Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

    Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging hyper-virulent strains (BI /NAP1/027, 078, 001) of C. difficile, and previous exposure to CDI that lead to recurrence. Higher incidence, increased treatment failures, and recurrence with standard therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

    About Fidaxomicin (OPT-80)

    Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

    About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel(TM) (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at

    Forward-looking Statements

    Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to treat CDI, address current treatment limitations and reduce the incidence of CDI. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts Optimer Pharmaceuticals, Inc. John Prunty, CFO & VP, Finance Christina Donaghy, Corporate Communications Manager 858-909-0736 Porter Novelli Life Sciences Jason I. Spark, Vice President 619-849-6005

    PRN Photo Desk, Optimer Pharmaceuticals, Inc.

    CONTACT: John Prunty, CFO & VP, Finance, or Christina Donaghy, Corporate
    Communications Manager, both of Optimer Pharmaceuticals, Inc.,
    +1-858-909-0736; or Jason I. Spark, Vice President of Porter Novelli Life
    Sciences, +1-619-849-6005, for Optimer Pharmaceuticals, Inc.

    Web Site:

    Aftersoft Network N.A. Inc Announces Release of OpenWebs Version 5

    ALLENTOWN, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Aftersoft Network N.A., Inc. a wholly owned subsidiary of Aftersoft Group, Inc. (BULLETIN BOARD: ASFG.OB) , a leading provider of business automation and ecommerce solutions for the automotive aftermarket, is pleased to announce the general release of OpenWebs, Version 5, (OW V5), completed after months of design and development. This latest version has been enhanced to use both Microsoft's .NET and Ajax (asynchronous JavaScript +XML) technologies. These changes have enhanced the system speed for inventory lookups while simultaneously requiring fewer page refreshes.

    OpenWebs is an ecommerce platform used by buyers and sellers in the automotive aftermarket to facilitate both system to system and browser to system electronic ordering. OpenWebs includes modules for business to business (B2B) as well as business to consumer (B2C) electronic commerce. OpenWebs is currently deployed at over thirty five tire & parts distributors and is connected to thousands of buyer service shops, jobbers and tire stores.

    Among various enhancements and benefits included in this version: -- Pearl TireGuide supported for Tire lookup in both B2B and B2C modules -- Google Checkout shopping cart added to the B2C tire module -- Tire B2C module has the option to order tires with or without installation and Road Hazard Warranty -- New Graphical User Interface for B2B Tire lookup screen -- Self-Service Accounts Receivable Status and Invoice Lookup -- Links to IAP (Internet Auto Parts) for part inquiries and orders with IAP member warehouses and stores -- Links to IPO (AAIA Internet Parts Ordering) for inquiries and orders with Beck/Arnley -- Links to AConneX for placing inquiries and orders with AConneX member warehouses and stores -- Links from AConneX for receiving inquiries and orders from 3rd party Point of Sale products -- Support for MS IE6, MS IE7, MS IE8, Firefox, Safari, and Google Chrome -- Supports Activant, AAIA, and Partslink Catalogs for parts distributors -- Supports kits and components for parts. -- User configurable pages for login page, home page and user pages. -- Display of local user-uploaded parts images -- Supports lost sales reporting

    "V.5 of OpenWebs has given our company a quantum leap forward in our E-commerce efforts. The intuitive nature of the program allows the user to order naturally with no hand holding," said Nick Staub, President and CEO of alternator & starter distributor, Romaine Electric. "In our business, we often sell components to rebuilders of rotating electrical products. No other online ordering system will show all component availability, pricing and interchanges on one query. We feel we have a leg up on our competition with OpenWebs!"

    "Real-time tire and parts lookup is now a necessity for distributors to compete in today's market. The average retail dealer will have multiple windows opened up to view various distributors ecommerce software," commented John Fischer, Vice President of Sales and Marketing, Aftersoft Network NA, Inc. "OpenWebs not only supports a browser based ordering system, but is leading the way with system to system connectivity. With OpenWebs, a dealer can view his distributor's inventory from within his own POS screen which saves time by creating the order on his supplier's system, adding the tire to his own customer work order, and creating a purchase order on his own system."

    About Aftersoft Group, Inc.

    Aftersoft Group, Inc. is a supplier of business and ERP supply chain management solutions to automotive parts manufacturers, distributors and retailers. Aftersoft Group provides the automotive aftermarket with a combination of business management systems, information products, and online services that together deliver benefits for all parties involved in the timely repair of a vehicle. For further information, please visit

    This press release contains forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the company's business including, increased competition; the ability of the company to expand its operations through either acquisitions or internal growth, to attract and retain qualified professionals, and to expand commercial relationships; technological obsolescence; general economic conditions; and other risks detailed time to time in filings with the Securities and Exchange Commission (SEC).

    Activant and AConneX are registered trademarks of Activant Solutions Inc.

    Partslink is a registered trademark of Automotive Body Parts Association.

    Aftersoft Group, Inc.

    CONTACT: John Fischer, Aftersoft Network NA, Inc., c. +1-740-632-6127,
    p. +1-740-266-7002,; or Sarah Jarvis, Aftersoft Group
    Inc., c: + 44 (0)771 517 0984, p: + 44 (0)1244 311 794,

    Web Site:

    Perfect World Announces Appointment to the Board of Directors

    BEIJING, Oct. 31 /PRNewswire-Asia/ -- Perfect World Co., Ltd. ("Perfect World" or the "Company"), a leading online game developer and operator in China, today announced the appointment of Mr. Daniel Dong Yang as an independent director to the Company's Board of Directors.

    (Logo: )

    Mr. Daniel Dong Yong has been a partner of SAIF Partners, an Asian private equity firm, since 2004 and served as a director from 2001 to 2004. He currently serves as a director of several companies, such as MainOne Information Technology Co., Ltd. and Mobi Antenna Technologies (Shenzhen) Co., Ltd. From 2000 to 2001, he served as an investment officer and director of Softbank China Venture Capital, a venture capital firm in China. Mr. Yang received his bachelor's degree in computer science from Tsinghua University in 1995, and his master degree in accounting from University of Southern California in 1997. Mr. Yang is a Chartered Financial Analyst.

    "I would like to welcome Mr. Yang to the Board as an independent director. His extensive experience will bring significant value to Perfect World," commented Mr. Michael Chi, Chairman and Chief Executive Officer of Perfect World.

    Perfect World would also like to announce that Mr. Louis T. Hsieh recently stepped down from his position as a member of the Board of Directors of Perfect World. He plans to focus on other professional commitments.

    "I would like to thank Mr. Louis T. Hsieh for his contribution to Perfect World," commented Mr. Michael Chi. "I and the rest of the Board would like to take this opportunity to express our sincere gratitude to Mr. Louis T. Hsieh and wish him the best in his pursuit of his other professional commitments."

    After the above changes of the board of directors, Perfect World has met the requirement of the Nasdaq Stock Market, Marketplace Rules that a majority of the directors shall be independent directors. Perfect World's current board members are Mr. Michael Chi, founder, chairman and Chief Executive Office of Perfect World, Mr. Ge Song, director, Mr. Daniel Dong Yong, independent director, Dr. Bing Xiang, independent director, and Mr. Han Zhang, independent director. The three independent directors are also members of the Company's audit committee.

    About Perfect World Co., Ltd. (

    Perfect World Co., Ltd. is a leading online game developer and operator based in China. Perfect World primarily develops online games based on proprietary game engines and game development platforms. The Company's strong technology and creative game design capabilities, combined with extensive local knowledge and experience, enable it to frequently and rapidly introduce popular games that are designed to cater to changing customer preferences and market trends in China. The Company's current portfolio of self-developed online games includes massively multiplayer online role playing games ("MMORPGs"): "Perfect World," "Legend of Martial Arts," "Perfect World II," "Zhu Xian," "Chi Bi," "Pocketpet Journey West," "Battle of the Immortals" and "Fantasy Zhu Xian;" and an online casual game: "Hot Dance Party." While a substantial portion of the revenues are generated in China, the Company's games have been licensed to leading game operators in a number of countries and regions in Asia, Europe and South America. The Company also generates revenues from game operation in North America. The Company plans to continue to explore new and innovative business models and remains deeply committed to maximizing shareholder value over time.

    Safe Harbor Statements

    This press release contains forward-looking statements. These statements constitute forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "future," "plans," "believes" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Potential risks and uncertainties include, but are not limited to, our limited operating history, our ability to protect our intellectual property rights, our ability to respond to competitive pressure, changes of the regulatory environment in China, and economic slowdown in China and/or elsewhere. Further information regarding these and other risks is included in Perfect World's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Perfect World does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For further information, please contact Perfect World Co., Ltd. Vivien Wang Investor Relations Officer Tel: +86-10-5885-1813 Fax: +86-10-5885-6899 Email: Christensen Investor Relations Kathy Li Tel: +1-480-614-3036 Fax: +1-480-614-3033 Email: Roger Hu Tel: +852-2117-0861 Fax: +852-2117-0869 Email:

    Beijing Perfect World Co., Ltd.

    CONTACT: Vivien Wang, Investor Relations Officer of Perfect World Co.,
    Ltd., +86-10-5885-1813, Fax: +86-10-5885-6899, or; Kathy Li,
    +1-480-614-3036, Fax: +1-480-614-3033, or, Roger Hu,
    +852-2117-0861, Fax: +852-2117-0869, or, both of
    Christensen Investor Relations for Perfect World Co., Ltd.

    Web Site:

    Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy EndpointsAranesp(R) (Darbepoetin Alfa) Did Not Reduce the Risk of Mortality, Cardiovascular Morbidity, or End Stage Renal Disease Results Show Increased Risk of Stroke Among Patients Treated to a Hemoglobin of 13 g/dL

    THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovascular morbidity, including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia, or end-stage renal disease (ESRD).

    The primary endpoints of the study were a composite of time to all-cause mortality or cardiovascular morbidity (including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia) and a composite of time to all-cause mortality or ESRD. Among the components of the primary cardiovascular composite endpoint, the risk of stroke increased by almost two-fold in patients in the Aranesp arm (101 patients [5.0 percent] vs. 53 patients [2.6 percent]; hazard ratio, 1.92; 95 percent confidence interval, 1.38 to 2.68; P<0.001). Although stroke is a recognized risk with erythropoiesis-stimulating agent (ESA) therapy, and has been identified in warnings in United States (U.S.) labeling since 2001, the risk observed in TREAT is of higher magnitude than that seen in previous clinical trials in CKD patients not on dialysis.

    A post hoc analysis indicates that there were no significant differences between treatment arms in the incidence of cancer or of all-cause deaths in patients who developed cancer during the trial. However, this analysis also showed an excess in overall mortality among patients in the Aranesp arm with a history of cancer. This finding requires further investigation.

    "ESAs were originally approved to raise red blood cell levels and to reduce the need for transfusions. In the TREAT study, we sought to demonstrate that, beyond these benefits, ESA therapy reduces cardiovascular morbidity and mortality. This hypothesis is not supported by the data," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "As the first, large-scale placebo-controlled study to examine the use of anemia therapy in diabetic CKD patients not on dialysis, the TREAT results demonstrated that in many diabetic CKD patients not on dialysis with moderate anemia, the risk of treatment to a target hemoglobin level of 13 g/dL will exceed the benefit of reducing the need for transfusions."

    Amgen has shared this information with global regulatory authorities and anticipates that the TREAT results will be included in labeling once discussions are complete.

    TREAT Study Design

    TREAT was an international, Phase 3, randomized, double-blind, placebo-controlled study of 4,038 CKD patients with type-2 diabetes and anemia. Designed as a superiority study to demonstrate improved cardiovascular outcomes, it is the largest study of ESA use in CKD patients to date. Patients enrolled in the study were randomized in a one-to-one ratio to receive either treatment with Aranesp to a target hemoglobin of 13 g/dL or placebo. Due to the increased risk of negative outcomes associated with low hemoglobin levels, patients in the control arm whose hemoglobin fell below 9 g/dL were given Aranesp as a rescue medication until their hemoglobin level reached 9 g/dL. Investigators were blinded to this intervention.

    TREAT had two primary endpoints. The first evaluated the time to all-cause mortality or cardiovascular morbidity including heart attack (myocardial infarction), congestive heart failure, hospitalization for angina (myocardial ischemia), or stroke (cerebrovascular accident). The second primary endpoint evaluated the time to all-cause mortality or chronic dialysis. TREAT was not designed to determine the appropriate hemoglobin target in this patient population.

    For patients randomized to the Aranesp group, the starting dose was 0.75 mcg/kg administered subcutaneously every two weeks; subsequent doses were titrated to achieve a hemoglobin target of 13.0 g/dL. Once the target hemoglobin was reached, the frequency of administration was extended to once-monthly. From 3 months to the end of treatment, the median achieved hemoglobin level was 12.5 g/dL (interquartile range, 12.0 to 12.8) in the Aranesp group and 10.6 g/dL (interquartile range, 9.9 to 11.3) in the placebo group. The average achieved hemoglobin level in the Aranesp-treated group exceeded current recommendations for anemia treatment as described in FDA-approved labeling.

    Chronic Kidney Disease: Impact and Prevalence

    CKD affects more than 26 million Americans and millions more worldwide. The disease is characterized by progressive kidney damage and impaired kidney function and is most often caused by type-2 diabetes or high blood pressure. When CKD progresses to kidney failure, chronic dialysis or a kidney transplant are required to sustain life. Anemia is a common complication of CKD that may begin in the early stages of the disease and becomes more common and severe as kidney function declines. Studies have shown that anemia is associated with an increased risk of mortality and cardiovascular morbidity in CKD patients.

    About Aranesp

    Aranesp was approved by the FDA in 2001 for the treatment of anemia associated with CRF for patients on dialysis and patients not on dialysis. The European Commission granted marketing authorization for the same indication in 2001 and subsequently updated it for CRF patients with symptomatic anemia in 2008.

    In 2002, the FDA approved Aranesp for the treatment of anemia caused by concomitantly administered chemotherapy in patients with nonmyeloid malignancies. The European Commission authorized the treatment of anemia caused by concomitantly administered chemotherapy in patients with non-haematological malignancies in 2002 and extended it to include non-myeloid malignancies in patients receiving chemotherapy in 2003.

    Important Aranesp Safety Information


    Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.


    -- ESAs shortened overall survival and/or time-to-tumor progression in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers when dosed to target a hemoglobin of greater than or equal to 12 g/dL.

    -- The risks of shortened survival and tumor progression have not been excluded when ESAs are dosed to target a hemoglobin of less than 12 g/dL.

    -- To minimize these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions.

    -- Use only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

    -- ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure. (This information is specific to the U.S. prescribing information)

    -- Discontinue following the completion of a chemotherapy course. Aranesp is contraindicated in patients with uncontrolled hypertension. All patients, including patients with cancer or chronic kidney failure:

    -- You may get serious heart problems such as heart attack, stroke, heart failure, and may die sooner if you are treated with Aranesp to a hemoglobin level above 12 g/dL.

    -- You may get blood clots at any time while taking Aranesp. If you are receiving Aranesp and you are going to have surgery, talk to your healthcare provider about whether or not you need to take a blood thinner to lessen the chance of blood clots during or following surgery. Clots can form in blood vessels (veins), especially in your leg (deep venous thrombosis or DVT). Pieces of a blood clot may travel to the lungs and block the blood circulation in the lungs (pulmonary embolus).

    About Amgen

    Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit

    Forward-Looking Statements

    This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Oct. 30, 2009 and expressly disclaims any duty to update information contained in this news release.

    No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

    In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

    The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

    CONTACT: Amgen, Thousand Oaks Emma Hurley: 202-585-9647 (media) Arvind Sood: 805-447-1060 (investors) (Logo:

    PRN Photo Desk, Amgen

    CONTACT: media, Emma Hurley, +1-202-585-9647, or investors, Arvind Sood,
    +1-805-447-1060, both of Amgen, Thousand Oaks

    Web Site:

    BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 DiabetesPrescribing Information Also Includes Updated Safety Information

    SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.

    "The expanded indication gives physicians the option to prescribe BYETTA as a first-line treatment, increasing the number of patients who may benefit from the medication and providing an opportunity to treat patients with BYETTA earlier in the disease," said Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "Type 2 diabetes is a complex disease, so it is essential that healthcare professionals and their patients have a wide array of treatments that can effectively control blood glucose levels."

    The approval of BYETTA as a monotherapy treatment was based on a clinical study of patients with type 2 diabetes who were unable to achieve glycemic control through diet and exercise alone. Study findings showed that patients treated with 5 mcg or 10 mcg of BYETTA as monotherapy reduced their A1C, a measure of average blood sugar over three months, by 0.7 percentage points and 0.9 percentage points, respectively, and lost 6.0 pounds and 6.4 pounds, respectively. Results of this study were published in Clinical Therapeutics in August 2008.(i)

    Among treatment-emergent adverse events, nausea was reported with the greatest incidence (5 mcg, 3 percent; 10 mcg, 13 percent). Hypoglycemia was reported in 5 percent of patients taking 5 mcg and 4 percent of patients taking 10 mcg, with no severe hypoglycemic events.

    In addition to the monotherapy indication, the FDA approved changes to the BYETTA Prescribing Information to incorporate updated safety information, including pancreatitis-related language added to the Warnings and Precautions section. This update addresses the alert issued by the FDA in August 2008. The new label also expands upon existing language regarding use of BYETTA in patients with renal impairment. In addition, the label has been amended to match the format the FDA currently uses for Prescribing Information. This label update is being communicated to physicians via a "Dear Healthcare Professional" letter, which will be available at

    "Patient safety is our foremost concern at Amylin and Lilly, and the BYETTA Prescribing Information represents an important way to communicate the information that healthcare professionals and patients need in order to use the medication safely and effectively," Kolterman continued. "Thus, the updated label offers the most current information about the benefit-risk profile of BYETTA as a foundational therapeutic choice for people with type 2 diabetes."

    BYETTA has been used by more than one million patients since market introduction in 2005. It has a proven history with more than 10 million prescriptions written and 6.5 years of clinical experience.

    About Diabetes

    Diabetes affects more than 24 million people in the United States and an estimated 246 million adults worldwide.(ii,iii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $174 billion per year in direct and indirect medical expenses.(iv)

    According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(v) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(vi) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vii,viii)

    About BYETTA® (exenatide) injection

    BYETTA is the first and only FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

    BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

    BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit

    Important Safety Information for BYETTA® (exenatide) injection

    Based on post-marketing data, BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have severe kidney problems, and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they have severe problems with their stomach, such as delayed emptying of the stomach (gastroparesis) or problems with digesting food. Severe allergic reactions can happen with BYETTA.

    The most common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly happens when first starting BYETTA, but may become less over time.

    These are not all the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

    For Prescribing Information and Medication Guide, visit About Amylin and Lilly

    Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at

    Through a long-standing commitment to diabetes care, Lilly seeks to provide patients with breakthrough treatments that enable them to live longer, healthier, and fuller lives. Since 1923, Lilly has been an industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products, visit

    Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at

    This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA may be affected by competition; unexpected new data; safety and technical issues; clinical trials not confirming previous results; pre-clinical trials not predicting future results; label expansion requests not being submitted in a timely manner or receiving regulatory approval; approved label expansions not producing the results we expect, or manufacturing and supply issues. The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin's and Lilly's most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin and Lilly undertake no duty to update these forward-looking statements.


    (i) Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-60.

    (ii) The International Diabetes Federation Diabetes Atlas. Available at: Accessed Oct. 2, 2009.

    (iii) "All About Diabetes." American Diabetes Association. Available at: Accessed Oct. 2, 2009.

    (iv) "Direct and Indirect Costs of Diabetes in the United States." American Diabetes Association. Available at: Accessed Oct. 2, 2009.

    (v) Saydah SH, Fradkin J and Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.

    (vi) Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737-47.

    (vii) Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2007;30 Suppl 1:S48-65.

    (viii) Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331-9.

    Amylin Pharmaceuticals, Inc.

    CONTACT: Anne Erickson of Amylin, +1-858-754-4443, cell,
    +1-858-349-3195,; or Kindra Strupp of Lilly,
    +1-317-277-5170, cell, +1-317-554-9577,

    Web Site:

    Entergy Issues Forward Looking Financial Update and Announces $750 Million Share Repurchase Program Authorization

    NEW ORLEANS, Oct. 30 /PRNewswire-FirstCall/ -- Entergy Corporation today issued 2010 earnings guidance assuming a business as usual operation for the full year, as well as post-spin financial outlooks for Entergy and Enexus Energy Corporation. In addition, Entergy outlined its preliminary three-year capital expenditure plan for the period 2010 through 2012.

    "We continue to take the actions necessary to complete the planned non-utility nuclear spin-off," said J. Wayne Leonard, Entergy's chairman and chief executive officer. "With line of sight on ultimate resolution in 2010, the Entergy Board of Directors has granted authority for an additional $750 million share repurchase program, following completion of an initial $500 million authorization in third quarter 2009. While it is expected the additional share repurchases under the new authorization will occur following spin-off completion in the near-term, consistent with the $500 million authorization, the incremental $750 million of share repurchase capacity is supported by the underlying business operations whether or not the spin-off transaction is completed."

    Earnings Guidance

    As the proposed spin-off date of Entergy's non-utility nuclear business is not yet known with certainty at this time, Entergy is initiating 2010 earnings guidance in the range of $6.40 to $7.20 per share on an operational basis, assuming a business as usual operation for the full year. As-reported earnings per share guidance ranges from $6.15 to $6.95 and reflects $(0.25) per share of projected dis-synergies associated with the spin-off and plans to enter into a nuclear services joint venture. Guidance for 2010 does not incorporate a special item for expenses, which were incurred beginning in 2008 and are expected to continue in 2010, anticipated in connection with outside services provided to pursue the spin-off. The level of these charges in 2010 will vary depending upon resolution of the spin-off.

    Post-Spin Long-term Financial Aspirations

    The companies continue to aspire to deliver superior value to owners as measured by total shareholder return. The companies believe top-quartile total shareholder returns are achieved by growing earnings, delivering returns at or above the risk-adjusted cost of capital, maintaining credit quality and flexibility, and deploying capital in a disciplined manner, whether for new investments, share repurchases, dividends or debt retirements. Financial aspirations for the period 2009 through 2014 include the following:

    Growing earnings: -- Entergy: Double digit compound annual earnings per share growth over the 2009 through 2014 horizon. -- Enexus: Earnings growth achieved by realizing $2.0 billion of Adjusted EBITDA in 2014 and / or through share repurchases. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, income taxes, depreciation and amortization and interest and dividend income, excluding decommissioning expense and other than temporary impairment losses on decommissioning trust fund assets. The Adjusted EBITDA aspiration is expected to be achieved from power price increases on open positions and / or deployment of capital resulting in additional EBITDA potential. In addition, Enexus anticipates periodic return of capital in the form of share repurchases, with current estimated Adjusted EBITDA levels supporting such distributions. Capital deployment: -- Entergy: A balanced capital investment / return program. As outlined in the Preliminary 2010 through 2012 Capital Expenditures discussion below, Entergy sees continued productive investment opportunity at the Utility in the coming years. Entergy aspires to fund this capital program without issuing equity, while maintaining a competitive capital return program. Given the financial profile of its vertically integrated utility operation, dividends are expected to be the primary form of return of capital, with the aspiration to retain its current dividend level (even after the spin-off of a substantial business) while balancing future growth thereon with competing investment opportunities. -- Enexus: A balanced capital investment / return program. Enexus expects to generate ongoing free cash flow that can be used for debt repayment, investment and / or distributions through share repurchases. Given the financial profile of its merchant nuclear operation, share repurchases are expected to be the primary form of return of capital. Credit quality and flexibility to manage risk and act on opportunities: -- Entergy: investment grade credit -- Enexus: BB / Ba range credit Planned Capital Expenditures - Preliminary

    The preliminary capital plan from 2010 through 2012 anticipates $7.1 billion for investment, including $2.7 billion of maintenance capital. The remaining $4.4 billion is for specific investments, as well as other initiatives.

    Members of Entergy's management will attend the 44th Edison Electric Institute (EEI) Financial Conference and participate in meetings on November 1-3, 2009, at which time the information included in this release will be discussed. Additional information regarding Entergy's forward looking financial update is available in Entergy's investor news release dated Oct. 30, 2009 and accompanying handout material, copies of which have been filed today with the Securities and Exchange Commission on Form 8-K and are available on Entergy's investor relations Web site at

    Entergy Corporation is an integrated energy company engaged primarily in electric power production and retail distribution operations. Entergy owns and operates power plants with approximately 30,000 megawatts of electric generating capacity, and it is the second-largest nuclear generator in the United States. Entergy delivers electricity to 2.7 million utility customers in Arkansas, Louisiana, Mississippi and Texas. Entergy has annual revenues of more than $13 billion and approximately 14,700 employees.

    In this news release, and from time to time, Entergy Corporation makes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Except to the extent required by the federal securities laws, Entergy undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    Forward-looking statements involve a number of risks and uncertainties. There are factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including (a) those factors discussed in (i) Entergy's Form 10-K for the year ended December 31, 2008, (ii) Entergy's Form 10-Q for the quarters ended March 31 and June 30, 2009, and (iii) Entergy's other reports and filings made under the Securities Exchange Act of 1934, (b) the uncertainties associated with efforts to remediate the effects of Hurricanes Gustav and Ike and the January 2009 Arkansas ice storm and recovery of costs associated with restoration, and (c) the following transactional factors (in addition to others described elsewhere in this news release and in subsequent securities filings): (i) risks inherent in the contemplated spin-off, joint venture and related transactions (including the level of debt to be incurred by Enexus Energy Corporation and the terms and costs related thereto), (ii) legislative and regulatory actions, and (iii) conditions of the capital markets during the periods covered by the forward-looking statements. Entergy cannot provide any assurances that the spin-off or any of the proposed transactions related thereto will be completed, nor can it give assurances as to the terms on which such transactions will be consummated. The transaction is subject to certain conditions precedent, including regulatory approvals and the final approval by the Board of Directors of Entergy.

    Entergy Corporation

    CONTACT: News Media, Chanel Lagarde, +1-504-576-4238,, or Investor Relations, Michele Lopiccolo,
    +1-504-576-4879,, both of Entergy Corporation

    Web Site:

    Fannie Mae publie son résumé mensuel de septembre 2009

    WASHINGTON, October 31 /PRNewswire/ --

    Le résumé mensuel de Fannie Mae (NYSE : FNM) pour le mois de septembre 2009 est maintenant disponible à l'adresse Ce résumé mensuel contient des renseignements sur les activités de Fannie Mae pour le mois de septembre et depuis le début de l'exercice quant à notre portefeuille de prêts hypothécaires bruts, à nos titres adossés à des créances hypothécaires et autres garanties, aux mesures du risque lié aux taux d'intérêt et aux taux de délinquance sérieux.

    Fannie Mae existe pour développer les logements abordables et pour apporter des capitaux mondiaux dans les communautés locales afin de servir le marché du logement américain. Fannie Mae a une charte fédérale et évolue sur le marché hypothécaire secondaire américain pour garantir que les instituts de crédit foncier et les autres prêteurs disposent de fonds suffisants à prêter à taux faibles aux acquéreurs de logement. Notre mission consiste à assister ceux qui logent l'Amérique.

    Fannie Mae

    Latressa Cox de Fannie Mae, +1-202-752-6707

    page 1    

    News archive of March 2018
    1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 

    News Archives of October 2009
    1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31  

    News Archives other dates
    0-C     D-L     M-R     S-Z